RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
With Blockbuster Sales Potential
Executive Summary
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.